HAOHAI BIOTEC6826.HKValuation Analysis

As of Oct 16, 2026, HAOHAI BIOTEC (6826.HK) trades at a P/E of 20.00x, P/B of 1.20x, P/S of 1.35x, and a dividend yield of 6.26%.
Longitudinal percentile comparison: P/E sits at the 70th percentile over the trailing 10Y window (vs. 90th percentile over 3Y); P/B sits at the 32nd percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 3rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 62nd percentile within its industry and the 73rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.95%, ranking at the 98th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 38.1 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 7.95% total shareholder yield, 6.26% is paid out as dividends and roughly 1.69% is implied to come from buybacks — both channels are meaningfully in play. HAOHAI BIOTEC operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.